XenoPort May Be Beneficiary of Biogen Patent Filings

Brian Abrahams, a Wells Fargo analyst, believes that Biogen

MS pill patents will be a positive boost for XenoPort

. Further patent applications could provide patent protection until 2032 for Biogen's BG-12, which should benefit XenoPort's '829 drug, an earlier stage derivative of BG-12, with added protection from generic competition. BIIB is currently up 1.5 percent in pre-market trading, while XNPT is currently unchanged.